Comparison of clinical traits for seasonal and perennial allergic rhinitis during allergen exposure

医学 鼻漏 优势比 置信区间 过敏原 过敏性结膜炎 鼻塞 内科学 过敏 皮肤病科 哮喘 免疫学 外科 鼻子
作者
Kunpeng Wang,Yuan Zhang,Lianqi Wan,Jingyun Li,Chengshuo Wang,Luo Zhang
出处
期刊:Allergy and Asthma Proceedings [OceanSide Publications, Inc]
卷期号:45 (3): 173-179 被引量:4
标识
DOI:10.2500/aap.2024.45.240009
摘要

Background: Allergic rhinitis (AR) is traditionally subdivided into seasonal AR (SAR) and perennial AR (PAR) according to the type of allergen and the occurrence of symptoms during the year. There are currently no reports on the comparison of trait profiles for SAR and PAR during the allergen exposure. Purpose: The purpose of this study was to analyze the clinical characteristics of SAR and PAR during respective allergen exposure periods to provide valuable information for the development of treatment strategies. Methods: This study was performed between August 1, 2021, and January 31, 2022, in the Department of Allergy, Beijing Tongren Hospital. We continuously included diagnosed SAR and PAR outpatients who volunteered to participate in the survey. A questionnaire with regard to medical history, severity of symptoms, and diagnosis and treatment status was collected. Results: A total of 296 patients with SAR and 448 with PAR were finally recruited. Patients with SAR had more severe rhinorrhea compared with patients with PAR (p < 0.001), whereas there was no statistically significant difference in the severity of itching, sneezing, and congestion between the two entities (p ≥ 0.05). Both the gritty and watery eyes of patients with SAR were noticeably more severe than those of patients with PAR (PTotal Ocular Symptom Score [PTOSS] < 0.001). AR symptom severity is mainly associated with the comorbid allergic conjunctivitis (odds ratio 1.94 [95% confidence interval, 1.21-3.09]). SAR patients and PAR patients show no statistically significant differences in terms of their frequency of visits, annual expenditure, and choice of medication treatment for AR (p > 0.05). The overall control under standard medication of both patients with PAR and those with SAR is not ideal, especially in SAR. Conclusion: The current cross-sectional study demonstrated that the patients with SAR exhibited more severe overall clinical symptoms than those with PAR, especially nasal rhinorrhea and gritty and watery eyes. Both of the two disease entities have poor control under standardized medication treatment, especially in SAR. Further multicenter longitudinal studies that involve larger and more diverse populations should be conducted to provide a more accurate and comprehensive understanding of the condition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吕小布完成签到,获得积分10
1秒前
1秒前
XMC2022发布了新的文献求助20
2秒前
TD完成签到,获得积分10
3秒前
mawanyu发布了新的文献求助10
3秒前
3秒前
神勇幻枫发布了新的文献求助10
5秒前
kkkk完成签到,获得积分20
5秒前
7秒前
高高的酸奶完成签到,获得积分10
8秒前
8秒前
星辰大海应助探探采纳,获得10
9秒前
11秒前
12秒前
chouhhh完成签到,获得积分20
13秒前
共享精神应助ali采纳,获得10
13秒前
Jasper应助Carrot采纳,获得10
13秒前
怕黑的海菡完成签到,获得积分10
14秒前
hs完成签到,获得积分10
15秒前
小白不白发布了新的文献求助10
16秒前
XMC2022完成签到,获得积分10
18秒前
大苏子哥哥完成签到,获得积分10
18秒前
yarkye发布了新的文献求助10
19秒前
20秒前
20秒前
chouhhh关注了科研通微信公众号
22秒前
风趣的映安完成签到,获得积分20
24秒前
连夜雪发布了新的文献求助30
24秒前
方东完成签到,获得积分10
25秒前
探探发布了新的文献求助10
25秒前
25秒前
25秒前
今后应助张钰婷啦啦啦采纳,获得10
27秒前
天真豪英完成签到 ,获得积分10
29秒前
29秒前
30秒前
风趣的映安关注了科研通微信公众号
32秒前
cxw应助缥缈耷采纳,获得10
33秒前
CipherSage应助山野的雾采纳,获得10
33秒前
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Metallurgy at high pressures and high temperatures 2000
Various Faces of Animal Metaphor in English and Polish 800
An Introduction to Medicinal Chemistry 第六版习题答案 600
Cleopatra : A Reference Guide to Her Life and Works 500
Fundamentals of Strain Psychology 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6341351
求助须知:如何正确求助?哪些是违规求助? 8156703
关于积分的说明 17143816
捐赠科研通 5397546
什么是DOI,文献DOI怎么找? 2859278
邀请新用户注册赠送积分活动 1837206
关于科研通互助平台的介绍 1687226